

Incyte Supports Wilmington Friends School Strategic Vision and Plan for the Future

- Incyte to purchase Wilmington Friends School Lower School property
- Wilmington Friends School to explore possibility of building a state-of-the-art lower school complex on their main campus

WILMINGTON, Del. – October 11, 2019 – Incyte announced today that the Company has entered into an agreement with Wilmington Friends School. Inc., which will enable the school to meet the needs of student and faculty and create a 21st Century educational experience.

Incyte will purchase the lower school property on the Wilmington Friends School campus at 20 Granite Road, Wilmington, Delaware. Wilmington Friends School will explore opportunities to create a brand new, state-of-the-art lower school building that best serves their students today and beyond--enabling them to fulfill the goals of increased interdivisional collaboration and contact, greater community inclusion, and a more eco-friendly physical plant.

Per the agreement, closing of the purchase is subject to certain standard closing conditions including an initial diligence period and a subsequent approval period.

In 2017, Incyte expanded its global headquarters in Wilmington, Delaware creating an integrated campus for collaboration and innovation as the Company works to deliver on its commitment of improving the lives of patients living with cancer and other serious diseases. This acquisition will provide Incyte with a long-term opportunity to expand its global headquarters campus in Wilmington. Any proposed development by Incyte on the property would occur following the completion of the new Wilmington Friends lower school, which is estimated to be in the Fall of 2023.

Incyte is proud to be a valuable, productive, and civic-minded corporate neighbor—we look forward to continuing to grow our presence in the Delaware community, bringing new jobs and further supporting the local economy.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at <u>www.incyte.com</u>.

Follow @Incyte on Twitter at <u>https://twitter.com/Incyte</u>.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including whether and when the Company will complete its purchase of the

referenced parcel from the Wilmington Friends School, contain forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including those risks detailed in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ending June 30, 2019. Incyte disclaims any intent or obligation to update these forward-looking statements.

#

Contact:

Media Catalina Loveman +1 302 498 6

+1 302 498 6171 <u>cloveman@incyte.com</u>